ObsEva Closes CHF32M Series A Financing
ObsEva, a Geneva, Switzerland-based biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine, closed a CHF32m (approximately €25.6m) Series A financing round. The round was led by Sofinnova Partners, and co-led by Sofinnova Ventures and Novo A/S. MS Ventures, the corporate venture capital fund of Merck Serono has taken a minority […]